Heron Therapeutics Inc (NASDAQ:HRTX) price on Thursday, April 10, fall -3.19% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.82.
A look at the stock’s price movement, the close in the last trading session was $1.88, moving within a range at $1.69 and $1.835. The beta value (5-Year monthly) was 1.397. Turning to its 52-week performance, $3.93 and $1.04 were the 52-week high and 52-week low respectively. Overall, HRTX moved -24.48% over the past month.
Heron Therapeutics Inc’s market cap currently stands at around $277.24 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 37.08M for the company’s revenue for the quarter, with a low and high estimate of 35.25M and 38.1M respectively. The average forecast suggests up to a 6.96% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 158.17M, representing a 9.62% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that HRTX is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend HRTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
HRTX’s current price about -17.78% and -11.40% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 37.17, while 7-day volatility ratio is 11.23% and 7.32% in the 30-day chart. Further, Heron Therapeutics Inc (HRTX) has a beta value of 1.38, and an average true range (ATR) of 0.17. Analysts have given the company’s stock an average 52-week price target of $7, forecast between a low of $5 and high of $9. Looking at the price targets, the low is -174.73% off current price level while to achieve the yearly target high, price needs to move -394.51%. Nonetheless, investors will most likely welcome a -284.62% jump to $7 which is the analysts’ median price.
If we refocus on Heron Therapeutics Inc (NASDAQ:HRTX), historical trading data shows that trading volumes averaged 1.38 over the past 10 days and 1.73 million over the past 3 months. The company’s latest data on shares outstanding shows there are 152.13 million shares.
The 0.91% of Heron Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 75.70% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 32.07 million on 2025-03-14, giving us a short ratio of 12.22. The data shows that as of 2025-03-14 short interest in Heron Therapeutics Inc (HRTX) stood at 2718.0 of shares outstanding, with shares short rising to 30.77 million registered in 2025-02-14. Current price change has pushed the stock 18.95% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the HRTX stock continues to rise going into the next quarter.
